Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Aspirin use and risk of colorectal cancer according to BRAF mutation status

This week's issue of the Journal of the American Medical Association investigates the aspirin use and risk of colorectal cancer according to BRAF mutation status.

News image

Aspirin use reduces the risk of colorectal carcinoma.

Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2, suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF–wild-type neoplastic cells.

Dr Reiko Nishihara and colleagues examined whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation.

The team collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study and the Health Professionals Follow-up Study until 2006, for cancer incidence and until 2012, for cancer mortality.

Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute hazard ratios for colorectal carcinoma incidence according to BRAF mutation status.

The team's main outcomes and measures included incidence of colorectal cancer cases according to tumor BRAF mutation status.

Regular aspirin use was associated with lower BRAF–wild-type cancer risk
Journal of the American Medical Association

Among 127,865 individuals, with 3,165,985 person-years of follow-up, the team identified 1226 incident rectal and colon cancers with available molecular data.

Compared with nonuse, regular aspirin use was associated with lower BRAF–wild-type cancer risk.

The team observed this association irrespective of status of tumor PTGS2 expression or PIK3CA or KRAS mutation.

In contrast, regular aspirin use was not associated with a lower risk of BRAF-mutated cancer.

Compared with no aspirin use, aspirin use of more than 14 tablets per week was associated with a lower risk of BRAF–wild-type cancer.

The research team found that the relationship between the number of aspirin tablets per week and colorectal cancer risk differed significantly by BRAF mutation status.

Dr Nishihara's team concludes, "Regular aspirin use was associated with lower risk of BRAF–wild-type colorectal cancer but not with BRAF-mutated cancer risk."

"These findings suggest that BRAF-mutant colon tumor cells may be less sensitive to the effect of aspirin."

"Given the modest absolute risk difference, further investigations are necessary to determine clinical implications of our findings."

JAMA 2013; 309(24): 2563-2571
26 June 2013

Go to top of page Email this page Email this page to a colleague

 29 July 2015

Advanced search
 29 July 2015 
Sitafloxacin-based triple therapy for H.pylori
 28 July 2015 
Lifestyle changes after colorectal cancer screening
 27 July 2015 
Fecal microbiota transplantation for severe C. difficile infection
 24 July 2015 
Causes of death in celiac disease
 23 July 2015 
Reduction in H. pylori prevalence
 22 July 2015 
Detection of esophageal eosinophilia and eosinophilic esophagitis
 21 July 2015 

Clinical outcomes for Barrett's esophagus neoplasia

 20 July 2015 
Certolizumab pegol for Crohn's disease
 17 July 2015 

Sexual dysfunction after rectal cancer treatment

 17 July 2015 
Genetic variation and gastric cancer
 17 July 2015 
Colitis associated with anti-CTLA-4 therapy
 16 July 2015 
Hormones and endometrial cancer in Lynch syndrome
 16 July 2015 
Lynch syndrome screening by microsatellite instability
 16 July 2015 
Relapse of IBD after discontinuation of anti-TNF therapy
 15 July 2015 
Aspergillus niger-derived enzymes
 15 July 2015 
Prophylactic omeprazole improves GI symptoms
 15 July 2015 
Risk prediction index for advanced colorectal cancer
 14 July 2015 
Combination therapies for chronic HCV
 14 July 2015 
Interferon- and ribavirin-free treatment regimen for HCV
 14 July 2015 
Cancer surveillance in ulcerative colitis
 13 July 2015 
Colon polyps in chronic inflammatory conditions of the colon
 13 July 2015 
Drugs and occult vs overt upper GI bleeds
 13 July 2015 
Anxiety and depression in functional GI disorders
 10 July 2015 
Daclatasvir in the treatment of chronic HCV
 10 July 2015 
Surveillance intervals to reduce colorectal cancer
 10 July 2015 
Stress and GI symptoms in IBD
 09 July 2015 
Opioid-induced esophageal dysfunction
 09 July 2015 
Predictive factors for metastasis in colorectal cancer
 09 July 2015 
Marker of response to medical therapy in Crohn's
 08 July 2015 

Nucleoside analogue therapy in HBeAg-negative chronic hepatitis B?

 08 July 2015 

Medical education in endoscopy training

 08 July 2015 
Chronic unexplained nausea and vomiting
 07 July 2015 
Anastomotic leak after elective surgery for colonic cancer
 07 July 2015 
Fecal transplantation for ulcerative colitis
 07 July 2015 
Obesity and risk of hepatocellular carcinoma
 06 July 2015 
Fecal microbiota transplantation
 06 July 2015 
Liver Failure–Sequential Organ Failure Scoring System
 06 July 2015 
Future colorectal surgery for metachronous cancers
 03 July 2015 
Tumors with mismatch-repair deficiency
 03 July 2015 
Aptitude of trainees in endoscopic ultrasonography
 03 July 2015 
Extracolonic pathologies in colorectal cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Anastomotic leak and cancer cancer
 02 July 2015 
Health care use by IBD children
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Oral mechanical bowel preparation
 01 July 2015 
Probiotics in IBD
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 29 June 2015 
Rescue therapy in ulcerative colitis
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Fecal microbiota in pediatric IBD
 24 June 2015 
Fatigue scales for IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us